Join Dr. Mariah Pierce, Technical Account Manager at Sino Biological, as she introduces Sino Biological's cutting-edge, high-throughput, cell-free expression platform. This platform facilitates the ...

Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...

Eurofins CDMO Alphora is developing and launching AI-powered software for high-throughput salt and co-crystal screening.

Nuclera extended its Series C with $12M, bringing total to $87M, to expand Protein Discovery with full-format antibody ...

Researchers at Nuclera completed the first Asian installations of its eProtein Discovery System at National Taiwan University ...

The most successful players — both old and new — are those focusing on operational risk control rather than assay novelty.

Creative Biolabs streamlines bispecific antibody development by merging genetic engineering, cell-free expression, and high-throughput screening into a single, comprehensive pipeline.

Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...

To battle this epidemic, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term (HEAL) Initiative in 2018. As part of this effort, scientists at the NIH National ...